Vytorin, Avandia raise doubt on FDA approvals

With recent studies raising questions about the safety of Avandia, and the benefits of costly cholesterol combo drug Vytorin, public debate has begun again as to whether the FDA's approval process for new medications is adequate. What's at issue, as controversy swirls around these and other challenged drugs, is whether the FDA should permit the use of "surrogate markers" in testing that allegedly reflect a drug's broader benefits. Drug makers like using these markers, as they can speed up approvals, but some observers argue that they aren't adequate.

As we noted yesterday, House Energy and Commerce Committee members sent letters this week to the American Heart Association and the American College of Cardiology, as well as drug makers Merck and Schering-Plough, to find out more about the medication. It's not clear yet whether a major crackdown is process, but it does seem likely that we're going to hear a lot of noise about this on the Hill in the near future.

To learn more about the controversy:
- read this Kaiser Daily Health Policy Report item

Related Articles:
AHA backs costly cholesterol drug combo. Report
Vytorin defenders funded by drugmakers. Report
Vytorin, Zetia scrips plummet. Report
Avandia gets black-box warning. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.